新抗原树突细胞疫苗接种与常规化疗相结合,用于患有晚期横向结肠癌的患者
Hideya Onishi1,2,3, Atsushi Higa1,2, Mayu Tasaki1,2
1Osaka Iseikai Cancer and Neurological Intractable Disease Treatment Clinic, 2-9-15-8F Higashinakajima, Higashiyodogawa-ku, Osaka, 533-0033, Japan.
Journal of surgical case reports
|January 8, 2026
概括
新抗原树突细胞 (DC) 疫苗接种在个性化癌症免疫疗法中显示出希望. 这种方法帮助结肠癌患者实现了无病生存,表明其在免疫监测癌症复发方面的潜在作用.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 基因组学就是基因组学.
背景情况:
- 新抗原树突细胞 (DC) 疫苗接种是一种个性化癌症免疫疗法.
- 基因组分析指导针对性治疗的新抗原鉴定.
- 需要更多关于新抗原DC疫苗接种疗效的数据.
研究的目的:
- 评估辅助性新抗原DC疫苗的临床效用和疗效.
- 评估新抗原直流疫苗接种对瘤标志物和免疫反应的影响.
- 研究T细胞在癌症免疫监测中识别新抗原的作用.
主要方法:
- 一名患有pStage IIIB横直肠癌的患者在手术后接受了辅助性新抗原DC疫苗接种.
- 常规化疗是同时进行六个月的.
- 监测了癌胚抗原 (CEA) 和细胞毒性T淋巴细胞 (CTL) 活性水平.
主要成果:
- 新抗原直流疫苗接种导致CEA水平升高的降低.
- 周围血液的CTLs表现出对新抗原的特定识别.
- 患者在手术后16个月保持无疾病状态.
结论:
- 新抗原直流疫苗接种可能是结肠癌的可行的辅助疗法.
- 识别瘤特异性新抗原的CTLs有助于免疫监测.
- 这一案例证明了个性化免疫疗法在实现长期缓解方面的潜力.
相关概念视频
Cancer Vaccines
946
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
946
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
564
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
564


